Sanofi forms mature-drugs partnership with Cheplapharm, taking 26.4% stake

Sanofi agreed to form a strategic partnership with Cheplapharm covering 20 mature medicines, with Cheplapharm set to acquire three manufacturing sites.

Sanofi will take a 26.4% equity stake in Cheplapharm as consideration, deepening a relationship that began in 2014.

Assets include Lovenox/Clexane outside the U.S.; the deal supports Sanofi’s shift toward innovation-focused growth.

Commercial transfer is expected to start in Q1 2027; the transaction is targeted to close in Q3 2027, subject to approvals.

Sanofi expects no impact on its 2026 financial guidance; additional financial terms are to be disclosed later.